Promising immunotherapy trial aims to replace harsh chemo for kids with relapsed leukemia
NCT ID NCT07476729
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests two immunotherapy drugs, inotuzumab and blinatumomab, in 750 children with relapsed B-cell acute lymphoblastic leukemia. The goal is to replace toxic chemotherapy with targeted, less harmful treatments to improve survival and reduce side effects. Participants are children aged 1 to 21 with a first relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Inotuzumab ozogamicin and blinatumomab
- What this could lead to
- If successful, this could establish less toxic immunotherapy as the new standard of care for children with relapsed B-cell ALL, improving survival and reducing side effects.
- What could go wrong
- This is a large phase 3 trial, but it hasn't started recruiting yet. The new drugs may not work better than current treatments, and there are risks like severe immune reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Acıbadem University
Istanbul, 34752, Turkey (Türkiye)
-
CHU de NICE, Hôpital L'ARCHET
Nice, 06202, France
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
-
Fakultni Nemocnice V Motole
Prague, 150 00, Czechia
-
Fundeni Clinical Institute, Pediatric Clinic Fundeni
Bucharest, Romania
-
Ghent University Hospital
Ghent, B-9000, Belgium
-
HUS Helsinki University Hospital
Helsinki, FIN-00290, Finland
-
Instituto Português de Oncologia de Lisboa
Lisbon, 1099-023, Portugal
-
Karolinska University Hospital
Solna, 171 64, Sweden
-
Ospedale Pediatrico Bambino Gesu
Rome, 00165, Italy
-
Prinses Máxima Centrum
Utrecht, 3584 CS, Netherlands
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Semmelweis University
Budapest, 1094, Hungary
-
St. Anna Kinderspital GmbH
Vienna, 1090, Austria
-
Tel Aviv Sourasky Medical Centre Dana-Dwek Children's Hospital
Tel Aviv, 64239, Israel
-
University Children's Hospital
Zurich, 8032, Switzerland
-
University Clinical Hospital Virgen De La Arrixaca
Murcia, 30120, Spain
-
University Medical Centre Ljubljana
Ljubljana, 1000, Slovenia
-
University Wroclaw
Wroclaw, 50 354, Poland
-
Univerzity Komenského a Národného
Bratislava, 833 40, Slovakia
More trials for these conditions
Other studies related to the condition(s) this trial covers.